TCGA-C8-A134-01A-11R-A115-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 13
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.510
- INTERFERON_ALPHA_RESPONSE+0.430
- MYC_TARGETS_V1+0.390
- INTERFERON_GAMMA_RESPONSE+0.380
- ALLOGRAFT_REJECTION+0.350
- MITOTIC_SPINDLE+0.330
- MTORC1_SIGNALING+0.310
- MYC_TARGETS_V2+0.300
- PI3K_AKT_MTOR_SIGNALING+0.270
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.470
- ESTROGEN_RESPONSE_LATE-0.350
- ANGIOGENESIS-0.340
- PANCREAS_BETA_CELLS-0.260
- PROTEIN_SECRETION-0.250
- ANDROGEN_RESPONSE-0.230
- FATTY_ACID_METABOLISM-0.170
- BILE_ACID_METABOLISM-0.160
- PEROXISOME-0.160
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCproject_0095_T3_RNA | — | E | 0.860 |
| 2 | TCGA-BH-A1FC-01A-11R-A13Q-07 | — | E | 0.853 |
| 3 | TCGA-E2-A1II-01A-11R-A144-07 | — | E | 0.836 |
| 4 | TCGA-E2-A1LI-01A-12R-A157-07 | — | E | 0.834 |
| 5 | 20100125.TNBC | — | E | 0.824 |
| 6 | TCGA-AR-A1AQ-01A-11R-A12P-07 | — | E | 0.824 |
| 7 | SRR33346961 | — | — | 0.817 |
| 8 | TCGA-A2-A0CM-01A-31R-A034-07 | — | E | 0.815 |
| 9 | TCGA-AR-A1AI-01A-11R-A12P-07 | — | E | 0.815 |
| 10 | TCGA-B6-A0X1-01A-11R-A109-07 | — | E | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.270 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| COMPLEMENT | 0.110 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |